Journal
NON-CODING RNA
Volume 9, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/ncrna9020029
Keywords
microRNAs; miR-145-5p; CFTR; miRNA therapy; agomiRNAs; pre-miRNAs
Ask authors/readers for more resources
This study aims to investigate the effects of molecules mimicking the activity of pre-miR-145-5p, pre-miR-335-5p, and pre-miR-101-3p on Calu-3 cells and discuss their potential applications in pre-clinical studies. The results show that treatment with agomiR-145-5p effectively inhibits CFTR gene expression and protein production. Therefore, agomiR pre-miR-145-5p should be considered as a therapeutic option for inhibiting CFTR gene expression in various pathological conditions.
(1) Background: MicroRNAs are involved in the expression of the gene encoding the chloride channel CFTR (Cystic Fibrosis Transmembrane Conductance Regulator); the objective of this short report is to study the effects of the treatment of bronchial epithelial Calu-3 cells with molecules mimicking the activity of pre-miR-145-5p, pre-miR-335-5p, and pre-miR-101-3p, and to discuss possible translational applications of these molecules in pre-clinical studies focusing on the development of protocols of possible interest in therapy; (2) Methods: CFTR mRNA was quantified by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR). The production of the CFTR protein was assessed by Western blotting; (3) Results: The treatment of Calu-3 cells with agomiR-145-5p caused the highest inhibition of CFTR mRNA accumulation and CFTR production; (4) Conclusions: The treatment of target cells with the agomiR pre-miR-145-5p should be considered when CFTR gene expression should be inhibited in pathological conditions, such as polycystic kidney disease (PKD), some types of cancer, cholera, and SARS-CoV-2 infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available